PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
通过 Kinome RNAi 筛选以 PI3K 和 MAPK 通路为靶点，与泛 HER 不可逆抑制剂 Neratinib 联合治疗 HER2 阳性乳腺癌和 TNBC
期刊:Biomedicines
影响因子:3.9
doi:10.3390/biomedicines9070740
Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S Lalani, Lisa D Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T Ueno
信号转导
肿瘤
乳腺癌
IHC
WB
MAPK/ERK
PI3K/Akt
p40
